Lilly presents 21 dermatology posters at Fall Clinical Dermatology 2026
- Lilly will present 21 poster presentations at the 2026 Fall Clinical Dermatology Conference, held Oct. 8–11 in Las Vegas.
- Thirteen posters cover EBGLYSS (lebrikizumab‑lbkz), including durable disease control, less frequent adolescent maintenance dosing, reduced topical use, pediatric data from six months, and involvement of hands and feet.
- Six presentations report on concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide), including an exploratory biomarker analysis from the TOGETHER‑PsO study in adults with moderate‑to‑severe plaque psoriasis and obesity or overweight with at least one weight‑related comorbidity.
- Long‑term durable outcomes with Olumiant (baricitinib) in patients 12 years and older with severe alopecia areata will be presented from BRAVE‑AA‑PEDS, the first and largest Phase 3 trial focused on pediatric severe AA.
Event and scope
Lilly will present 21 poster presentations at the 2026 Fall Clinical Dermatology Conference, taking place Oct. 8–11 in Las Vegas, covering atopic dermatitis, psoriasis and alopecia areata.
EBGLYSS (lebrikizumab‑lbkz)
Thirteen posters on EBGLYSS explore durable disease control, evidence for less frequent maintenance dosing in adolescents, reduced need for topical treatments, investigational efficacy and safety in pediatric patients as young as six months, and outcomes in patients with disease affecting high‑impact areas such as the hands and feet.
Taltz (ixekizumab) and Zepbound (tirzepatide) concomitant use
Six presentations examine the concomitant use of Taltz and Zepbound, including an exploratory biomarker analysis from the TOGETHER‑PsO study of adults with moderate‑to‑severe plaque psoriasis and obesity or overweight with at least one weight‑related comorbid condition, to probe immunometabolic links and the potential impact of combining therapies versus Taltz alone.
Olumiant (baricitinib) in pediatric alopecia areata
Long‑term durable outcomes from the BRAVE‑AA‑PEDS Phase 3 trial will report Olumiant data in patients aged 12 years and older with severe alopecia areata; BRAVE‑AA‑PEDS is described as the first and largest Phase 3 study specifically designed to evaluate pediatric severe AA.
Source: Lilly